MX2022005809A - Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente del regulador de la conductancia a nivel transmembranario de la fibrosis quistica (cftr). - Google Patents
Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente del regulador de la conductancia a nivel transmembranario de la fibrosis quistica (cftr).Info
- Publication number
- MX2022005809A MX2022005809A MX2022005809A MX2022005809A MX2022005809A MX 2022005809 A MX2022005809 A MX 2022005809A MX 2022005809 A MX2022005809 A MX 2022005809A MX 2022005809 A MX2022005809 A MX 2022005809A MX 2022005809 A MX2022005809 A MX 2022005809A
- Authority
- MX
- Mexico
- Prior art keywords
- cystic fibrosis
- transmembranial
- heteroarylaminosulphonamides
- cftr
- conditions mediated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/222—Amides of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934293P | 2019-11-12 | 2019-11-12 | |
| PCT/US2020/060180 WO2021097057A1 (en) | 2019-11-12 | 2020-11-12 | 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient cftr activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005809A true MX2022005809A (es) | 2022-06-08 |
Family
ID=73740547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005809A MX2022005809A (es) | 2019-11-12 | 2020-11-12 | Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente del regulador de la conductancia a nivel transmembranario de la fibrosis quistica (cftr). |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240002374A1 (OSRAM) |
| EP (1) | EP4058439A1 (OSRAM) |
| JP (2) | JP7721517B2 (OSRAM) |
| CN (1) | CN115003659B (OSRAM) |
| AU (1) | AU2020384279A1 (OSRAM) |
| BR (1) | BR112022009185A2 (OSRAM) |
| CA (1) | CA3158057A1 (OSRAM) |
| CL (1) | CL2022001245A1 (OSRAM) |
| CO (1) | CO2022007953A2 (OSRAM) |
| EC (1) | ECSP22046050A (OSRAM) |
| IL (1) | IL292966A (OSRAM) |
| JO (1) | JOP20220105A1 (OSRAM) |
| MX (1) | MX2022005809A (OSRAM) |
| PE (1) | PE20221461A1 (OSRAM) |
| PH (1) | PH12022551139A1 (OSRAM) |
| WO (1) | WO2021097057A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3088577A1 (en) | 2018-02-15 | 2019-08-22 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| US11873300B2 (en) | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| CA3157798A1 (en) | 2019-11-12 | 2021-05-20 | Zhongli Gao | 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity |
| EP4225737A1 (en) * | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| IL303519A (en) | 2020-12-10 | 2023-08-01 | Vertex Pharma | Cystic fibrosis treatment methods |
| CN113480416B (zh) * | 2021-07-12 | 2023-03-21 | 重庆大学 | 一种芳基酮的制备方法 |
| WO2023189602A1 (ja) | 2022-03-30 | 2023-10-05 | 石原産業株式会社 | ピリダジノン系化合物又はその塩及びそれらを含有する有害生物防除剤 |
| CN114835655A (zh) * | 2022-04-14 | 2022-08-02 | 河南师范大学 | 一种合成光学活性三氟甲基丙烯酸酯类化合物的方法 |
| WO2024097227A1 (en) | 2022-10-31 | 2024-05-10 | Sionna Therapeutics | Methods of treating cftr-mediated diseases or disorders |
| WO2025017207A1 (en) * | 2023-07-20 | 2025-01-23 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Inhibitors of smndc1 and their therapeutic use |
| WO2025076235A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU654125B2 (en) * | 1991-03-07 | 1994-10-27 | Hisamitsu Pharmaceutical Co., Inc. | Novel diphenylthyazole derivative |
| AU689972B2 (en) * | 1994-11-29 | 1998-04-09 | Hisamitsu Pharmaceutical Co., Inc. | Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof |
| EP1441732A2 (en) * | 2001-11-08 | 2004-08-04 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivative and pharmaceutical use thereof |
| MXPA06002567A (es) * | 2003-09-06 | 2006-09-04 | Vertex Pharma | Moduladores de transportadores con casete de union de atp. |
| RS57024B1 (sr) * | 2011-06-10 | 2018-05-31 | Medimmune Ltd | Anti-pseudomonas psl vezujući molekuli i njihova upotreba |
| WO2016183173A1 (en) * | 2015-05-12 | 2016-11-17 | Avista Pharma Solutions | Antiparasitic compounds |
| US10138227B2 (en) * | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
| TW201811766A (zh) * | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
| WO2024097227A1 (en) * | 2022-10-31 | 2024-05-10 | Sionna Therapeutics | Methods of treating cftr-mediated diseases or disorders |
-
2020
- 2020-11-12 PH PH1/2022/551139A patent/PH12022551139A1/en unknown
- 2020-11-12 MX MX2022005809A patent/MX2022005809A/es unknown
- 2020-11-12 AU AU2020384279A patent/AU2020384279A1/en active Pending
- 2020-11-12 JP JP2022527081A patent/JP7721517B2/ja active Active
- 2020-11-12 CN CN202080092755.2A patent/CN115003659B/zh active Active
- 2020-11-12 EP EP20820656.5A patent/EP4058439A1/en active Pending
- 2020-11-12 CA CA3158057A patent/CA3158057A1/en active Pending
- 2020-11-12 BR BR112022009185A patent/BR112022009185A2/pt unknown
- 2020-11-12 PE PE2022000772A patent/PE20221461A1/es unknown
- 2020-11-12 WO PCT/US2020/060180 patent/WO2021097057A1/en not_active Ceased
- 2020-11-12 IL IL292966A patent/IL292966A/en unknown
-
2022
- 2022-05-10 JO JOP/2022/0105A patent/JOP20220105A1/ar unknown
- 2022-05-11 US US17/742,169 patent/US20240002374A1/en active Pending
- 2022-05-12 CL CL2022001245A patent/CL2022001245A1/es unknown
- 2022-06-03 CO CONC2022/0007953A patent/CO2022007953A2/es unknown
- 2022-06-09 EC ECSENADI202246050A patent/ECSP22046050A/es unknown
-
2025
- 2025-07-30 JP JP2025126773A patent/JP2025160375A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020384279A1 (en) | 2022-05-26 |
| PE20221461A1 (es) | 2022-09-21 |
| CA3158057A1 (en) | 2021-05-20 |
| BR112022009185A2 (pt) | 2022-07-26 |
| CO2022007953A2 (es) | 2022-09-09 |
| IL292966A (en) | 2022-07-01 |
| PH12022551139A1 (en) | 2023-07-17 |
| JP2023500408A (ja) | 2023-01-05 |
| CN115003659B (zh) | 2026-04-21 |
| JOP20220105A1 (ar) | 2023-01-30 |
| CN115003659A (zh) | 2022-09-02 |
| US20240002374A1 (en) | 2024-01-04 |
| CL2022001245A1 (es) | 2023-03-10 |
| ECSP22046050A (es) | 2022-08-31 |
| WO2021097057A1 (en) | 2021-05-20 |
| JP7721517B2 (ja) | 2025-08-12 |
| JP2025160375A (ja) | 2025-10-22 |
| KR20220115829A (ko) | 2022-08-18 |
| EP4058439A1 (en) | 2022-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022007953A2 (es) | Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr | |
| JOP20220106A1 (ar) | مجموعات سلفون أميد أمينو أريل غير متجانس بها 6 ذرات لعلاج أمراض وحالات يتوسط في حدوثها نشاط cftr | |
| MX2024002519A (es) | Compuestos de indol y metodos de uso. | |
| MX2023004923A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| EA202191361A1 (ru) | Способы лечения муковисцидоза | |
| CY1124432T1 (el) | Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη | |
| CY1125488T1 (el) | Παραγωγα πυριδινης και θεραπευτικες χρησεις αυτων ως αναστολεις trpc6 | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| EP4684836A3 (en) | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases | |
| MX2019013954A (es) | Inhibidores covalentes de kras. | |
| MX2020002806A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso. | |
| MX2019002439A (es) | Derivados de n-(piridin-2-il) piridina-sulfonamida y su uso en el tratamiento de enfermedades. | |
| SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
| MX2019006637A (es) | Modulador del regulador de conductancia transmembrana de fibrosis quistica composiciones farmaceuticas metodos de tratamiento y proceso para producir el modulador. | |
| PH12023552741A1 (en) | Psilocybin Compositions, Methods Of Making And Methods Of Using The Same | |
| EP4603148A3 (en) | Deuterium-enriched pirfenidone and methods of use thereof | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| CN116829173A8 (zh) | 药物配制品 | |
| MX2023005913A (es) | Derivados de bencenosulfonamida y usos de los mismos. | |
| EA201991817A1 (ru) | Интраназальная композиция, включающая бетагистин | |
| MX2017012188A (es) | Inhibidores de beta-secretasa 1 (bace1). | |
| WO2024086799A3 (en) | Lipid nanoparticles and methods of using the same for treating cell proliferative diseases and disorders | |
| JOP20240265A1 (ar) | مركبات وتراكيب وطرق استخدامها | |
| EA202092013A1 (ru) | Пиридинкарбонильные производные и их терапевтические применения в качестве ингибиторов trpc6 | |
| EA202090298A1 (ru) | Способы лечения муковисцидоза |